JP2006501479A - コラーゲンペプチドの比、それらの使用および生成物 - Google Patents
コラーゲンペプチドの比、それらの使用および生成物 Download PDFInfo
- Publication number
- JP2006501479A JP2006501479A JP2004541914A JP2004541914A JP2006501479A JP 2006501479 A JP2006501479 A JP 2006501479A JP 2004541914 A JP2004541914 A JP 2004541914A JP 2004541914 A JP2004541914 A JP 2004541914A JP 2006501479 A JP2006501479 A JP 2006501479A
- Authority
- JP
- Japan
- Prior art keywords
- neoepitope
- osteoarthritis
- progression
- ratio
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 18
- 102000008186 Collagen Human genes 0.000 title abstract description 18
- 108010035532 Collagen Proteins 0.000 title abstract description 18
- 229920001436 collagen Polymers 0.000 title abstract description 18
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 87
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 52
- 206010023203 Joint destruction Diseases 0.000 claims abstract description 40
- 206010003246 arthritis Diseases 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 56
- 230000008859 change Effects 0.000 claims description 40
- 230000009885 systemic effect Effects 0.000 claims description 17
- 230000003628 erosive effect Effects 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 14
- 230000002917 arthritic effect Effects 0.000 claims description 13
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 9
- 210000000845 cartilage Anatomy 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 5
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 230000003349 osteoarthritic effect Effects 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 abstract 1
- 210000001503 joint Anatomy 0.000 description 20
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 108010041390 Collagen Type II Proteins 0.000 description 14
- 102000000503 Collagen Type II Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 210000003127 knee Anatomy 0.000 description 10
- 210000001188 articular cartilage Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 208000008558 Osteophyte Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000001258 synovial membrane Anatomy 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000011382 collagen catabolic process Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 208000023073 Heberden node Diseases 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008414 cartilage metabolism Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101150082216 COL2A1 gene Proteins 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000011227 chondrocyte hypertrophy Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000034311 hand osteoarthritis Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41432402P | 2002-09-30 | 2002-09-30 | |
| PCT/US2003/030853 WO2004031725A2 (en) | 2002-09-30 | 2003-09-30 | Ratios of collagen peptides, their uses and products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501479A true JP2006501479A (ja) | 2006-01-12 |
| JP2006501479A5 JP2006501479A5 (enExample) | 2006-10-19 |
Family
ID=32069723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004541914A Pending JP2006501479A (ja) | 2002-09-30 | 2003-09-30 | コラーゲンペプチドの比、それらの使用および生成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040132064A1 (enExample) |
| EP (1) | EP1549354A4 (enExample) |
| JP (1) | JP2006501479A (enExample) |
| KR (1) | KR20050084608A (enExample) |
| AU (1) | AU2003279076A1 (enExample) |
| CA (1) | CA2500670A1 (enExample) |
| WO (1) | WO2004031725A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009257842A (ja) * | 2008-04-14 | 2009-11-05 | Ttc:Kk | 変形性関節症の検査方法及び診断用キット |
| JP2010520449A (ja) * | 2007-03-02 | 2010-06-10 | アナマル メディカル アクチボラゲット | Ｉｘ型コラーゲン破壊の診断 |
| JP2013539027A (ja) * | 2010-09-24 | 2013-10-17 | ノルディック・ビオサイエンス・エー／エス | Ｉｉ型コラーゲンバイオマーカーのアッセイ |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009038771A2 (en) * | 2007-09-19 | 2009-03-26 | Massachusetts Institute Of Technology | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
| GB0820786D0 (en) * | 2008-11-13 | 2008-12-24 | Nordic Bioscience As | Assessment of protein degradation by measurement of collagen fragments |
| US9829493B2 (en) | 2013-07-15 | 2017-11-28 | Steven J. Svoboda | Methods and apparatus for assessment of risk for joint injury |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6132976A (en) * | 1992-12-04 | 2000-10-17 | Shriners Hospitals For Children | Immunoassays for the measurement of collagen denaturation and cleavage in cartilage |
| IE970801A1 (en) * | 1997-11-11 | 1999-05-19 | Helsinn Chemicals Ireland Ltd | An apparatus for producing a pharmaceutical product |
-
2003
- 2003-09-30 AU AU2003279076A patent/AU2003279076A1/en not_active Abandoned
- 2003-09-30 US US10/673,647 patent/US20040132064A1/en not_active Abandoned
- 2003-09-30 EP EP03770587A patent/EP1549354A4/en not_active Withdrawn
- 2003-09-30 JP JP2004541914A patent/JP2006501479A/ja active Pending
- 2003-09-30 KR KR1020057005375A patent/KR20050084608A/ko not_active Withdrawn
- 2003-09-30 WO PCT/US2003/030853 patent/WO2004031725A2/en not_active Ceased
- 2003-09-30 CA CA002500670A patent/CA2500670A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520449A (ja) * | 2007-03-02 | 2010-06-10 | アナマル メディカル アクチボラゲット | Ｉｘ型コラーゲン破壊の診断 |
| JP2009257842A (ja) * | 2008-04-14 | 2009-11-05 | Ttc:Kk | 変形性関節症の検査方法及び診断用キット |
| JP2013539027A (ja) * | 2010-09-24 | 2013-10-17 | ノルディック・ビオサイエンス・エー／エス | Ｉｉ型コラーゲンバイオマーカーのアッセイ |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050084608A (ko) | 2005-08-26 |
| CA2500670A1 (en) | 2004-04-15 |
| WO2004031725A3 (en) | 2005-02-24 |
| EP1549354A4 (en) | 2005-11-23 |
| EP1549354A2 (en) | 2005-07-06 |
| AU2003279076A8 (en) | 2004-04-23 |
| AU2003279076A1 (en) | 2004-04-23 |
| US20040132064A1 (en) | 2004-07-08 |
| WO2004031725A2 (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Belasco et al. | Psoriatic arthritis: what is happening at the joint? | |
| Garnero et al. | Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis | |
| Greenspan et al. | Precision and discriminatory ability of calcaneal bone assessment technologies | |
| Charni et al. | Urinary type II collagen helical peptide (HELIX‐II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis | |
| Demers et al. | Biochemical markers and skeletal metastases | |
| Jansen et al. | The combination of the biomarkers urinary C‐terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy | |
| Jung et al. | Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis | |
| Wininger et al. | Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery | |
| US8058013B2 (en) | Assessing risk of disease progression in rheumatoid arthritis patients | |
| Kim et al. | The relationship between synovial fluid VEGF and serum leptin with ultrasonographic findings in knee osteoarthritis | |
| Ohrndorf et al. | Detailed Joint Region Analysis of the 7‐Joint Ultrasound Score: Evaluation of an Arthritis Patient Cohort over One Year | |
| Niki et al. | Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy | |
| US12332250B2 (en) | Inflammatory biomarkers for predicting responsiveness to FGF-18 compound | |
| JP2024105273A (ja) | Ｆｇｆ－１８化合物に対する反応性を予測する代謝バイオマーカー | |
| Hashimoto et al. | A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs | |
| Ehrle et al. | Synovial fluid and serum concentrations of interleukin-1 receptor antagonist and interleukin-1ß in naturally occurring equine osteoarthritis and septic arthritis | |
| Park et al. | Visual assessment of chest computed tomography findings in anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis: is it associated with airway abnormalities? | |
| JP2006501479A (ja) | コラーゲンペプチドの比、それらの使用および生成物 | |
| CN101523218B (zh) | 评估类风湿性关节炎患者疾病进展的风险 | |
| JP4189033B2 (ja) | 定量的関節炎状態のアッセイ | |
| Hussain Manik et al. | Ultrasound assessment of synovial thickness of some of the metacarpophalangeal joints of hand in rheumatoid arthritis patients and the normal population | |
| Gabusi et al. | Cartilage and bone serum biomarkers as novel tools for monitoring knee osteochondritis dissecans treated with osteochondral scaffold | |
| Port et al. | Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials | |
| Emery | Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes | |
| Forsblad-d'Elia et al. | Bone mineral density by digital X-ray radiogrammetry is strongly decreased and associated with joint destruction in long-standing rheumatoid arthritis: a cross-sectional study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060904 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090619 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091001 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |